Home › Compare › UFFRF vs ABBV
UFFRF yields 1540.83% · ABBV yields 3.06%● Live data
📍 UFFRF pulled ahead of the other in Year 1
Combined, UFFRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of UFFRF + ABBV for your $10,000?
Unifin Financiera, S. A. B. de C. V. operates as a leasing company in Mexico. The company operates through Leases, Factoring, and Others Loans segments. It provides leasing facilities for motor vehicles, such as cars, trucks, helicopters, aircraft, and ships; and machinery and equipment, as well as the assets of various industries in the middle-sized enterprise sector. The company also offers liquidity and financial solutions to customers by acquiring or discounting accounts receivables; financing for the working capital needs and the purchase of other capital goods; and granting loans for the acquisition of new or used vehicles to individuals and legal entities. In addition, it is involved in obtaining loans; guaranteeing obligations; and issuing, subscribing, accepting, endorsing, selling, discounting, and pledging various types of credits, as well as acting as administrator for guarantee trusts. Further, the company provides damage and theft, mayor medical expenses, auto, home, civil liability, life, and surety bail bonds insurance products. Unifin Financiera, S. A. B. de C. V. was incorporated in 1993 and is based in Mexico City, Mexico.
Full UFFRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.